Filtered Products

Liver targeted transfection reagents leverage the natural tropism of the liver—fenestrated endothelial cells with 80–100 nm pores—along with an optimized lipid formulation strategy to achieve highly efficient delivery without the need for additional targeting ligands. They enable robust transfection of ASO, siRNA, mRNA, circRNA, and other nucleic acids in both animal models and cells.

The spleen, as the largest peripheral immune organ, is rich in T cells, B cells, NK cells, and dendritic cells (DCs), and plays a central role in immune response regulation and tumor immune surveillance. Spleen targeted transfection reagents achieve selective enrichment in the spleen through optimized lipid composition without the need for targeting ligand modifications, enabling efficient transfection of ASO, siRNA, mRNA, circRNA, and other nucleic acids in both animal models and cells.

Lung targeted transfection reagents achieve selective organ targeting through formulation optimization and are specifically designed for efficient delivery of ASO, siRNA, mRNA, circRNA, and other nucleic acid therapeutics to lung tissues. These products are intended for basic research and preclinical translational applications in pulmonary diseases including cystic fibrosis, idiopathic pulmonary fibrosis, lung cancer, acute lung injury, and respiratory infections.

Gene editing targeted transfection reagents enable efficient delivery of CRISPR-Cas9 gene-editing tools and adenine base editors to target organs or cells, achieving a complete closed-loop workflow from organ targeting to tool delivery to functional efficacy.

Immunocyte targeted transfection reagents achieve precise delivery of nucleic acid therapeutics to immune cells through optimized lipid composition and targeting modification strategies. Built upon the spleen-targeting transfection reagent platform, these products extend targeting from the organ level to the cellular level, overcoming the limitation of conventional LNPs that focus solely on organ targeting and offering more precise tools for research on immune-related diseases.

Skin targeted transfection reagents are specifically developed for localized cutaneous delivery, employing subcutaneous or intradermal injection to achieve efficient enrichment of nucleic acid therapeutics—including ASO, siRNA, mRNA, and circRNA—in skin tissues. They provide a novel delivery technology platform for applications in skin cancer, medical aesthetics, and advanced functional skincare (gene-based skincare).

SM102 LNP standard reagents strictly adhere to the benchmark Moderna formulation, featuring SM102 ionizable lipid as the core component, precisely formulated with phospholipids, cholesterol, and PEG-lipids at defined molar ratios to form a stable and efficient nucleic acid delivery system. The ready-to-use kit eliminates the need for in-house synthesis, seamlessly bridging the complete R&D pipeline from in vitro mechanistic studies to in vivo animal model validation.